| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1373039 | Bioorganic & Medicinal Chemistry Letters | 2008 | 6 Pages |
Abstract
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is a potential target for treatment of diabetes and metabolic syndrome. Docking and pharmacophore modeling have been used to discover novel inhibitors of 11β-HSD1. Several compounds, with large structural diversity and good potency against 11β-HSD1, have been found and their potency was determined by the enzyme assay. New scaffolds of 11β-HSD1 inhibitors are also reported.
Graphical abstractDocking and pharmacophore Modeling were used to discover novel inhibitors of 11β-HSD1. Several compounds with large structural diversity and good potency were found. New scaffolds are reported.Figure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Huaiyu Yang, Wei Dou, Jing Lou, Ying Leng, Jianhua Shen,